329 related articles for article (PubMed ID: 26028398)
41. More recent, better designed studies have weakened links between antidiabetes medications and cancer risk.
Dankner R; Roth J
Diabet Med; 2020 Feb; 37(2):194-202. PubMed ID: 31769894
[TBL] [Abstract][Full Text] [Related]
42. Incorporating New Medications in Diabetes Care.
Comi RJ
Ann Intern Med; 2015 Nov; 163(9):719-20. PubMed ID: 26458033
[No Abstract] [Full Text] [Related]
43. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238
[TBL] [Abstract][Full Text] [Related]
44. Oral diabetes medications: an update for home health clinicians.
Jacobs JA; Fetzer SJ
Home Healthc Nurse; 2013 Jan; 31(1):E1-13. PubMed ID: 23238625
[TBL] [Abstract][Full Text] [Related]
45. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes.
Charbonnel B
Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387
[No Abstract] [Full Text] [Related]
46. Metformin + saxagliptin for type 2 diabetes.
Scheen AJ
Expert Opin Pharmacother; 2012 Jan; 13(1):139-46. PubMed ID: 22149373
[TBL] [Abstract][Full Text] [Related]
47. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
[TBL] [Abstract][Full Text] [Related]
48. Can genetics improve precision of therapy in diabetes?
Groop L; Storm P; Rosengren A
Trends Endocrinol Metab; 2014 Sep; 25(9):440-3. PubMed ID: 25028244
[TBL] [Abstract][Full Text] [Related]
49. Evolving therapeutic options for type 2 diabetes mellitus: an overview.
Guthrie RM
Postgrad Med; 2012 Nov; 124(6):82-9. PubMed ID: 23322141
[TBL] [Abstract][Full Text] [Related]
50. Clinical decisions. Management of type 2 diabetes.
Goldberg RB; Holman R; Drucker DJ
N Engl J Med; 2008 Jan; 358(3):293-7. PubMed ID: 18199869
[No Abstract] [Full Text] [Related]
51. The impact of diabetes and diabetes medications on bone health.
Gilbert MP; Pratley RE
Endocr Rev; 2015 Apr; 36(2):194-213. PubMed ID: 25738213
[TBL] [Abstract][Full Text] [Related]
52. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.
Yassin SA; Aroda VR
Drug Des Devel Ther; 2017; 11():923-937. PubMed ID: 28356718
[TBL] [Abstract][Full Text] [Related]
53. [Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].
Valerón PF; de Pablos-Velasco PL
Med Clin (Barc); 2013 Sep; 141 Suppl 2():20-5. PubMed ID: 24444520
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
Fass AD; Gershman JA
Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
[TBL] [Abstract][Full Text] [Related]
55. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
56. Thiazolidinedione derivatives in type 2 diabetes mellitus.
Tack CJ; Smits P
Neth J Med; 2006 Jun; 64(6):166-74. PubMed ID: 16788214
[TBL] [Abstract][Full Text] [Related]
57. Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study.
Enders D; Kollhorst B; Engel S; Linder R; Verheyen F; Pigeot I
J Diabetes Complications; 2016; 30(7):1339-46. PubMed ID: 27245402
[TBL] [Abstract][Full Text] [Related]
58. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
Bailey T
Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074
[TBL] [Abstract][Full Text] [Related]
59. Diabetes update: new drugs to manage type 2 diabetes.
Erlich DR; Slawson DC; Shaughnessy A
FP Essent; 2013 May; 408():20-4. PubMed ID: 23690375
[TBL] [Abstract][Full Text] [Related]
60. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
Kim SC; Schneeweiss S; Glynn RJ; Doherty M; Goldfine AB; Solomon DH
Ann Rheum Dis; 2015 Nov; 74(11):1968-75. PubMed ID: 24919467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
